Ascomp With Codeine
NDC Package 0722-6094-05
Package Information
Ascomp With Codeine is contraindicated for: •All children younger than 12 years of age [see Warnings and Precautions (5.4)] •Postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see Warnings and Precautions (5.5)].ASCOMP with CODEINE is also contraindicated in patients with:•Significant respiratory depression [see Warnings and Precautions (5.8)] •Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions (5.8)] •Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions (5.9)/Drug Interactions (7)]. Marketed by Nexgen Pharma, Inc., this product is identified by NDC 0722-6094 and is authorized under FDA application ANDA075231.
Identification & Billing
- RxCUI: 994237 - butalbital 50 MG / aspirin 325 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule
- RxCUI: 994237 - aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule
- RxCUI: 994237 - ASA 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule
- RxCUI: 994239 - Ascomp with Codeine 50 MG / 325 MG / 40 MG / 30 MG Oral Capsule
- RxCUI: 994239 - aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0722 - Nexgen Pharma, Inc.
- 0722-6094 - Ascomp With Codeine
- 0722-6094-05 - 500 CAPSULE in 1 BOTTLE
- 0722-6094 - Ascomp With Codeine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0722-6094). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0722-6094-05 identifies a specific commercial package of 500 capsule in 1 bottle of Ascomp With Codeine, labeled by Nexgen Pharma, Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Nexgen Pharma, Inc. on November 30, 2001. The current certification is valid through December 31, 2021.
How is this Nexgen Pharma, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00722609405. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.